MITA lukewarm on CMS' PET decision
Article Thumbnail ImageOctober 1, 2013 -- The Medical Imaging and Technology Alliance (MITA) cited progress in the U.S. Centers for Medicare and Medicaid Services' (CMS) final decision on beta-amyloid PET coverage; however, the organization said it was disappointed by the scope.

To get access to this article and all of the content on AuntMinnie.com, create a free account or sign-in now.

Member Sign In:
MemberID or E-mail Address:  
Do you have a AuntMinnie.com password?
No, I want a free membership.
Yes, I have a password:  


On September 27, CMS issued a final decision approving beta-amyloid PET under the agency's coverage with evidence development (CED) protocol for patients enrolled in an approved clinical study.

Although MITA appreciates that CMS is offering beta-amyloid PET to some Medicare beneficiaries, the group is disappointed there will not be coverage for beta-amyloid PET without CED for patients with suspected dementia or Alzheimer's disease who meet specific appropriate-use criteria.

The organization will continue to work with CMS toward a substantive, feasible CED program that will support broader access for Medicare patients, according to Gail Rodriguez, executive director of MITA.